RATING

Outlook

Positive

SECTOR

Biological Product (except Diagnostic) Manufacturing

Chief Sustainability Officer

Jose Francisco Vallejo Carrera

Contact Details:

T: N/A

E-mail: N/A

Stock Exchange and Ticker

BIT: 1SAN

Website

Sanofi

Contact

T: +33 (0)1 53 77 40 00

E.mail: N/A

Listing

#464 Best Employers for Diversity (2023)
#194 Canada’s Best Employers (2023)
#236 World’s Top Female-Friendly Companies (2022)
#48 World’s Best Employers (2022)
America’s Best Employers By State (2022)
#64 Best Employers for Women (2022)
#99 Global 2000 (2022)
#269 America’s Best Employers (2021)

Awards

S&P Global Silver Class (86 out of 100 points)
Sustainalytics: 22.9, Medium risk
Dow Jones Sustainability Index
MSCI: A Rating, 4th among the 6 largest pharma companies
CDP: A for Climate Change, A for Water
ISS-oekom: B rating, 1st decile of the 476 companies in the industry
FTSE4Good: 4.⅖, high rating sccross the 3 ESG pillars
Access to Medicine Index: 3.47/5 top 5 companies
WDi (Workforce Disclosure initiative): 92%
Vigeo Eiris: 62/100, 1st pharmaceutical company out of 57
Sanofi once again ranks in the top third of companies in the official French gender equality index

Revenue

$37.75B

Market Capitalisation

$100.885B

Employees

95,442

Content source

Sanofi Sustainability Report

Evaluation of Sanofi

Sustainability Scorecard

Sanofi Company Activity

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists of the commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France. (Source: Forbes)

Sanofi Sustainability Activity - As per company declarations

Sanofi reports on the SDGs targets and progress in their annual Corporate Social Responsibility report which, also shows the advancement and implementation of its CSR strategy since 2020, along four key pillars:

Affordable access to medicines, where Sanofi has made significant progress since the launch of its Global Health Unit (GHU) a year ago (2020). The launch of an impact investment fund that will support start-up companies and other innovators that can deliver scalable solutions for sustainable healthcare in underserved regions. In parallel, Sanofi GHU is also launching Impact®, the new GHU dedicated brand for non-profit distribution which will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries.
The focus on R&D for unmet needs including the elimination of sleeping sickness has been a longstanding mission for Sanofi, where the company continues to do more to change the treatment paradigm for the most vulnerable communities.
As part of Sanofi’s efforts for Planet Care, the company announced its ambition to be carbon neutral by 2030 and net zero by 2050 last year (2020), which marks an acceleration of 20 years versus its previous commitments. This year, Sanofi will outline its roadmap to reach carbon neutrality by 2030 and illustrate the positive impact of carbon offsetting programs on communities as well as the environment, contributing to its 2050 net zero commitment.
To ensure its Diversity, Equity & Inclusion (DE&I) strategy is rightly executed, monitor progress on the company’s 2025 targets, and learn from external thought-leaders, Sanofi announced the creation of its first DE&I board in April 2022.

Certificate & Labels, Standards and Frameworks

Sustainability Accounting Standards Board (SASB)
Task Force on Climate-related Financial Disclosures (TCFD)
Global Reporting Initiative (GRI)
Science-Based Target Initiative (SBTi)
Intergovernmental SciencePolicy Platform on Biodiversity and Ecosystem Services (IPBES)
Antimicrobial Resistance (AMR)
ISO 17020
ISO 50001
ISO 45000
ISO 14001
OHSAS
LEED
BREEAM
HQE
AAALAC International

Sanofi in the news: Press Reviews and Social Media

Highlights from Sanofi Sustainability Report

Targets vs Progress Reported

Target	Results reported
To help eradicate sleeping sickness by 2030 To help eradicate polio Maintain a price cap on some malaria treatments such as ASAQ Winthrop® at less than $1 for adults and $0.50 for children Donate 100,000 vials a year to treat people with rare diseases Help establish and enhance sustainable healthcare systems for people with chronic diseases that require long-term care Help reduce the burden on low and intermediate-income countries of non-communicable diseases like childhood cancer, diabetes, and mental health disorders Donate 100,000 vials a year to treat people with rare diseases, via the Humanitarian Program launched by Sanofi Genzyme	- Since the start of Sanofi’s collaboration with the WHO, the number of cases of sleeping sickness has fallen from 26,950 in 2001 to 663 in 2020, dropping below 1,000 for the third consecutive year - At the end of 2020, Sanofi’s total contribution to this WHO program (the program against neglected tropical diseases, especially sleeping sickness) was $100 million. Since then, the collaboration agreement was renewed for a further five years, to the tune of $25 million ($5 million a year)r - Sanofi informed healthcare authorities at the end of 2020, about the presence of nitrosamine impurities in certain batches of rifampicin-family antibiotics. The position adopted by the authorities, including the FDA, is that the risk of interrupting tuberculosis treatment outweighs the potential risk from the presence of nitrosamines. Therefore the healthcare authorities have temporarily raised the upper limit for nitrosamine so that all the drug companies involved can release their products. (authors’ note: transparency regarding the wrongdoing, as well as remedies proposed to address it)
Achieve gender balance in Sanofi Senior Leaders by 2025 Achieve 40% of women in executive posts by 2025	- 47.7% of women in the workforce
Reduce water consumption in the industrial R&D and tertiary sites by 15% by 2030 (relative to 2019) Implement efficient water management plans by 2025 for 100% of priority sites and by 2030 for all sites	- Water consumption (withdrawal of surface water, groundwater, water from public supply) went down by 11% from 33.4 (millions of m3/year) in 2020 to 31.4 - Sanofi reviewed the water program in 2021 in order to improve the response to current and future challenges and concluded that since water is a local resource, the target for reducing water withdrawal is by aggregating the local targets (rather than vice versa)
IReuse/recycle/recover at least 90% of the waste by 2025 Achieve landfills disposal rate below 1% of total waste by 2025 All new products to be eco-designed by 2025 No vaccines supplied in blister packs by 2027	- The 3R rate was 74% (excluding on-site recycling of solvents) - The landfill disposal rate in 2021 was 7% and 74 sites no longer used landfill (versus 66 sites in 2020) - Overall, the total waste generated by Sanofi was 4% lower than in 2019
55% reduction in greenhouse gas emissions from industrial, R&D and tertiary sites for Scope 1 & 2 (including medical rep fleet) by 2030, relative to 2019 Carbon neutrality by 2030 and net zero emissions by 2050 (Scopes 1, 2, & 3) Sanofi pledged to optimize their vehicle fleet so that by 2030 the vehicle fleet should have a neutral carbon footprint	- Total direct and indirect CO2e emissions showed a sharp fall of 25% between 2019 and 2021, against a target reduction of 10%, mainly due to the ramp-up: of our renewable electricity supply plan; the start-up of a decarbonized value supply chain via initiatives such as biomethane use; and the concentration of certain of its activities

UN SDGs Compliance Analysis

Progress made toward SDG targets
As reported by Sanofi

During 2021, Sanofi focused its efforts on developing a remediation plan to reduce or eliminate the impurities. In parallel, the ongoing clinical trial in children has been temporarily suspended while the situation is assessed by the authorities
In 2019, Sanofi, Unitaid, and the Global Fund to Fight AIDS, Tuberculosis and Malaria negotiated a ground-breaking volume-based agreement that reduces the public-sector price of a three-month course of rifapentine by nearly 70% in 100 low-income and middle-income countries affected by TB and by TB/HIV coinfection. The agreement was implemented in 2020 and has enabled many countries and programs to offer patients access to effective and shorter treatments for latent TB
In 2021, Sanofi supplied 50.5 million inactivated polio vaccine (IPV) doses to UNICEF for countries eligible for GAVI funding (the Vaccine Alliance). Sanofi Pasteur (the vaccines division of Sanofi) also supplied 31 million doses to Brazil, India, Indonesia, and the Philippines for their national polio vaccination campaigns
In 2021, more than 8 million ASAQ Winthrop (a drug developed with the non-profit Drugs for
Neglected Diseases Initiative (DNDi)) malaria treatments were sold at preferential prices, despite a marked slowing of demand due to the global prioritization of major programs, itself caused by the COVID-19 crisis
In 2021, a total of 110,000 vials were donated, enabling more than 1,000 patients with rare diseases to receive treatment. The program now reaches patients in 70 countries across six continents. It has been extended to new countries, following the first approvals in Mozambique and Senegal

2021 has been about a more all-round embedding of the culture to create high levels of awareness and understanding among all Sanofi employees, using a hybrid approach – sustaining the bottom-up effort, while adding top-down activities:
- awareness: an online employee space providing a holistic resource on “Play to Win” from strategy to culture, an online toolkit in seven key languages with concrete tools, tips, and tricks on how to activate the behaviors, and culture workshops in countries and for global teams;
- education: an eLearning module in seven key languages;
- storytelling: roundtable discussions between Executive Committee members and employees called “Candid Chats” and testimonials on real-life examples of living the behaviors;
- dedicated support: coaching provided to Executive Committee members and the senior leadership team.
- “Leading by Example” program, launched in 2020 supports leaders and teams who face many different business challenges and obstacles related to teamwork.
- In 2021, more than 120 fit-for-purpose workshops and interventions were facilitated, including coaching and team building.
- The follow-up Culture Barometer in June 2021, followed by the “Your Voice” survey at the end of 2021, showed a 10% uplift in awareness and a significant 15% uplift in employees seeing their managers demonstrate the “Play to Win” behaviors, compared to 2020 results.
- Beyond traditional ways to fill positions, managers are given rapid access to skilled resources by launching the global Talent Marketplace in the career management tool.
- Successfully piloted in 2021, this will be extended in 2022 so that all managers can use automated skills matching to staff projects with talents from across the company. This digital initiative is expected to accelerate cross-functional moves, improve career experiences, and give Sanofi a competitive advantage in attracting talent. As a result:
  - 89% of high potential talents are in the succession pipeline;
  - 1,155 employees moved to a new position in another function in 2021;
  - In 2021, the turnover rate of our high potential talents in senior and executive positions was 5.2%
  - Every employee owns the creation and execution of an impactful Individual Development Plan (IDP) based on the 70-20-10 model (70-20-10 model is based on the fact that learning comes 70% from job-related experiences, 20% from interactions with others, and 10% from more formal training), with support from their manager and HR, as a key approach for development and growth.
  - As a result, an IDP has been completed or is in progress for 69% of all employees in scope and more than 90% for high potential employees.
  - in 2021 to deploy our Career Hub, a centralized platform that enables employees to identify and access various career development opportunities, using different tools and resources such as Talent Marketplace, job shadowing, and mentoring
  - Sanofi has invested substantially in offering multiple learning opportunities that are critical for the company’s competitive advantage and success in tomorrow’s world:
    - Launched in March 2020, Sanofi University is a key resource for Sanofi’s employees to own their skills for today and tomorrow. It empowers everyone to drive their own development, helping to unleash their potential and equip them to “Play to Win”.
    - In 2021, the number of training hours per employee receiving training increased by approximately 3% (24.1h/employee

For LGBTQIA+ talents, Sanofi has partnered with MyGwork to attract more diverse profiles beyond gender balance

By 2030, in order to improve water quality by reducing pollution, eliminating dumping of waste at sea, reducing emissions of chemicals and hazardous materials to a minimum and significantly scale up recycling and reuse globally with no threat to water, Sanofi implemented a life cycle management plan at priority production sites by 2025
In 2021 Sanofi again completed the Water Security questionnaire of the Carbon Disclosure Project (CDP), obtaining the highest rating of A. This recognizes the achievement in consistently reducing the water footprint of our industrial operations over several years

The Sanofi quality management system is wholly in line with the requirements described in guideline Q10, “Pharmaceutical Quality System”, published by the International Council on Harmonization (ICH). It also incorporates all good practice rules:

– Good Clinical Practice (GCP)

– Good Distribution Practice (GDP),

– Good Laboratory Practice (GLP),

– Good Manufacturing Practice (GMP), and

– Good Pharmacovigilance Practice (GPVP)

The Global Quality Audit activities obtained ISO 17020:2012 certification in July 2019 (this certificate is available for 2 years)
In 2021 Sanofi conducted 210 internal quality audits, (including Sanofi entities and third-party audits), out of which 38 recalls with 3 Class 1 recalls

Sanofi set up an internal Bioethics Committee in 2012 to ensure that scientific and medical activities are conducted to high ethical standards, and with a view to constant improvement. The internal Bioethics Committee draws on recommendations from an Advisory Bioethics Council (ABC) (no info available for this council)
By 2025, Sanofi will have performed assessments on all newly-launched medicines, regardless of whether there is any regulatory requirement to do so. We will also deploy pilot schemes to promote the responsible use of medicines, and the proper disposal of unused medicines, medical devices, and packaging. Those pilot schemes will form the basis of a global program, to be rolled out by 2030

Since 2016, Sanofi has been gradually rolling out a program to evaluate and reduce the environmental impact of potential releases of pharmaceutical substances from the manufacturing sites. At the end of 2021, this program covered 63% of our chemical synthesis and dosage form
sites, and 100% of Sanofi’s priority sites (which are identified on the basis of risk analysis by substance and by site)
Sanofi is proactively assessing the environmental impact of the active ingredients in the products they sell, starting with the company’s strategic products. The efforts in this field are being supported by research partnerships with various stakeholders, including universities and other manufacturers. To date, the evaluation program has already covered 47% of those substances
We also support unused medicine collection schemes (like the Cyclamed scheme in France) in many countries.
Sanofi conducts awareness campaigns to help patients use medicines properly, especially antibiotics
In accordance with Sanofi’s own HSE policy and regulatory requirements, all sites are equipped with containment systems and/or systems for collecting accidental releases to prevent them from penetrating the soil. There is also a systematic multi-year soil and groundwater monitoring and evaluation program for our sites, both for those with ongoing operations and those being sold. Where necessary, remediation work is carried out following detailed evaluations
In cooperation with national and local authorities, Sanofi regularly assesses the rehabilitation work required and carries out such work when appropriate. Long-term rehabilitation work is in progress or planned at Mount Pleasant and Portland in the United States; Frankfurt in Germany; Brindisi in Italy; Dagenham in the United Kingdom; Ujpest in Hungary; Beaucaire,
Valernes, Limay, Neuville, and Vitry in France; and at a number of sites divested to third parties and covered by contractual environmental guarantees granted by Sanofi
Sanofi may also have potential liability for investigation and cleanup at several other sites, for which they have established provisions for the sites already identified and to cover contractual guarantees for environmental liabilities for sites that have been divested. In France specifically,

Sanofi has provided the financial guarantees for environmental protection required under French regulations

In 2021, Sanofi spent €49 million on rehabilitating sites previously contaminated by soil or groundwater pollution

Objectives to reduce emission Scope 1, 2, 3 have been validated by the Science Based Target initiative (SBTi)
In 2020, Sanofi signed up for the RE100 initiative, reinforcing its ambition to use 100% renewably-sourced electricity across the entire Sanofi scope by 2030
As a Gold Member of the RE100 initiative, Sanofi increased the use of renewables from 26% of our electricity consumption in 2020 to 59% in 2021.
In 2021, 30 of our sites received ISO 50001 certification (Energy Management Systems)
The renewables Sanofi uses are accredited under the Renewable Electricity Certificates (REC) program
Sanofi has a renewable electricity Power Purchase Agreement with ENEL in Mexico to supply energy to three Mexican sites.
Natural gas continues to be the highest source of electricity for Sanofi and the 2% reduction between 2021, relative to 2020 reflects energy efficiency programs, and also the concentration of operations on a single site
Energy consumption data include the following:
- Natural gas went down by 2% since 2019
- Electricity that includes the country-level energy mix, but excludes renewable electricity sourced from Sanofi in-house projects decreased by 55%
- Renewables (electricity and biofuels) increased by 400% since 2019
- Other energy sources (bought-in steam, waste-to-energy, etc.) decreased by 3%

Alongside efforts to make our buildings and processes more energy efficient, we have introduced a policy for sales rep travel (including vehicle buying and eco-driving courses) that cut CO2 emissions by 47% between 2019 and 2021
Sanofi has policies in place for managing the use of refrigerants, which include switching to substitute refrigerants with a lower global warming impact, improving leak prevention, and systematically analyzing accidental discharges. Since 2019, we have reduced the impact of refrigerant discharges by 28%, equivalent to 20,000 tonnes of CO2 equivalent
Total direct and indirect CO2e emissions showed a sharp fall of 25% between 2019 and 2021, against a target reduction of 10%, mainly due to the ramp-up: of our renewable electricity supply plan; the start-up of a decarbonized value supply chain via initiatives such as biomethane use; and the concentration of certain of its activities
In France, in 2021, such emissions represented 147,611 tonnes of CO2e in 2021 (including 3,900 tonnes for our medical rep vehicle fleet), down 16% on the 2020 level (175,729 tonnes of CO2e, including 4,234 tonnes for our medical rep vehicle fleet)
Greenhouse gases (tonnes of CO2) from Scope 1 and Scope 2 decreased by 25% from 2019

Sanofi acknowledges that Scope 3 emission calculations are based on a wide range of data, so there is a high degree of uncertainty. However there are a few steps they’ve taken to improve accuracy:
- Scope 3 was calculated for the 15 categories listed in the Greenhouse Gas (GHG) protocol
- In 2020, they brought the methodology and calculations in-house, to improve the quality of the data collected and fine-tune the assumptions
- Sanofi views all categories as important and analyzes them with the relevant players, which makes it possible to measure our Science Based Target initiative (SBTi) commitment
- During 2021, Sanofi developed an online tool to consolidate, analyze and simulate data sourced from all our stakeholders, which allows the comparison of data by model, organization and year, and recalibrate baseline year values. This aims to improve transparency by disclosing values that are comparable from one year to the next because they use the same scope and apply the same assumptions

Sustainability Certificates, Awards and Listings

Sanofi Sustainability Report

RATING

SECTOR

Chief Sustainability Officer

Stock Exchange and Ticker

Website

Contact

Listing

Awards

Revenue

Market Capitalisation

Employees

Content source

Sanofi Sustainability Report

Evaluation of Sanofi

Sustainability Scorecard

Sanofi Company Activity

Sanofi Sustainability Activity - As per company declarations

Certificate & Labels, Standards and Frameworks

Sanofi in the news: Press Reviews and Social Media

Highlights from Sanofi Sustainability Report

Targets vs Progress Reported

UN SDGs Compliance Analysis

Sustainability Certificates, Awards and Listings

About Us

By Audience

Impakter Platforms